title: Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
authors.forename: C
authors.initials: C
authors.lastname: Serrate
authors.forename: Y
authors.initials: Y
authors.lastname: Loriot
authors.forename: T
authors.initials: T
authors.lastname: De La Motte Rouge
authors.forename: M
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: B
authors.initials: B
authors.lastname: Escudier
authors.forename: A
authors.initials: A
authors.lastname: Bossi
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D016879:Salvage Therapy; D043823:Taxoids / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen